Rite Aid’s June sales results include Brooks/Eckerd
CAMP HILL, Pa. For the first time including the Brooks/Eckerd stores in its same-store sales results, Rite Aid on Thursday posted a decline of 0.4 percent in overall comp sales for the four weeks ending June 28, which represented a 0.5 percent decrease in pharmacy same-store sales and a 0.2 percent decline in front-end same-store sales.
Rite Aid’s core store base improved 2.6 percent on an overall same-store basis, with a 2.6 percent lift in pharmacy same-store sales and growth of 2.9 percent across its front-end year-ago results.
Accordingly, the Brooks/Eckerd same-store sales decreased overall 6.2 percent over the prior-year period. Pharmacy same-store sales decreased 5.4 percent and front-end same-store sales were down 8.1 percent.
Total drugstore sales for the four-week period dropped 2.5 percent to $2 billion.
Prescription revenue accounted for 66.5 percent of drugstore sales, and third party prescription revenue represented 96.4 percent of pharmacy sales.
FDA to increase security for committee members in advisory meetings
WASHINGTON The Food and Drug Administration is planning on beefing up its security at advisory committee meetings, in hopes of restoring order after an incident at a recent meeting, according to The Regulation Policy Market Report.
According to reports, an intoxicated speaker in the audience at a recent meeting began a threatening rant. This isn’t the first time there have been disturbances at an advisory committee, they usually occur when the drug in question is used to treat rare-or life-threatening disease.
While the FDA hasn’t made a formal announcement of the policy changes, Office of New Drug director John Jenkins discussed the new procedures at the Drug Information Association’s annual meeting last week.
“We have put in place some new measures to help improve security at meetings,” Jenkins said. “If we anticipate that there may be an increased need for security at a particular meeting because it is a particularly controversial topic, we may have additional security procedures.”
Those procedures include:
1) Creating a physical barrier by roping off the committee from the public. The intent, Jenkins said, is “to put some separation between those who might become agitated in the audience and committee members.”
2) Increasing the presence of security guards in the committee room—both in uniform and street clothes.
3) Reading a statement at the start of the meeting about “good rules of behavior.”
FDA approves Eisai’s Aciphex for ages 12 and up
WOODCLIFF LAKE, N.J. The Food and Drug Administration has approved Aciphex for treatment of gastroesophageal reflux disease in adolescents age 12 and older, Tokyo-based Eisai’s North America subsidiary announced Monday.
Aciphex, known generically as rabeprazole sodium, is available in 20 mg tablets for treating GERD for up to eight weeks.
Eisai discovered and developed the drug and promotes it in the United States with PriCara, a division of Ortho-McNeil-Janssen Pharmaceuticals.